Story Highlights
- The DOJ found that Black and Hispanic applicants had substantially higher admission rates at Yale School of Medicine despite lower average GPAs and test scores than white and Asian applicants
- Yale is the second medical school targeted this month, following similar findings sent to the UCLA David Geffen School of Medicine last week
- Assistant Attorney General Harmeet Dhillon called Yale’s continued practices a “willful failure to comply” with the Supreme Court’s 2023 ban on race-based admissions
What Happened
The Department of Justice sent a formal letter Thursday to Yale University’s legal counsel accusing the Yale School of Medicine of ongoing race-based admissions discrimination that violates federal civil rights law and the Supreme Court’s landmark 2023 ruling in Students for Fair Admissions v. Harvard. The letter was authored by Harmeet Dhillon, the assistant attorney general for civil rights, who concluded a yearlong investigation that reviewed multiple admissions cycles, internal data, and university policy documents.
Dhillon’s letter stated that across the past three admissions cycles, Black and Hispanic applicants were admitted to the Yale School of Medicine at significantly higher rates than white and Asian applicants, despite having lower average grade-point averages and test scores. The DOJ characterized this disparity as evidence of intentional racial discrimination that persisted after the Supreme Court explicitly prohibited race-conscious admissions at American universities. “Yale has continued its race-based admissions program despite the Supreme Court and the public’s clear mandate for reform,” Dhillon said in a statement accompanying the letter.
The investigation also examined a brief that Yale submitted to the Supreme Court in the Students for Fair Admissions case, in which the university argued it could not maintain racially diverse classes without explicitly considering race. The DOJ noted that Yale’s admissions outcomes remained similarly diverse even after the 2023 ruling — which, in the department’s analysis, demonstrated that race was still being factored into decisions through methods designed to obscure direct consideration. Dhillon described this as evidence of a deliberate effort to circumvent the law.
Yale University responded cautiously. Karen Peart, the university’s associate vice president for communications, said Yale would carefully review the DOJ’s letter and expressed confidence in its admissions process. Yale School of Medicine stated it was “confident in the rigorous admissions process we follow.” Neither statement indicated plans to alter the university’s approach or to accept the DOJ’s characterization of the data.
Why It Matters
The targeting of Yale School of Medicine carries particular symbolic and practical weight. Yale is among the most prestigious medical institutions in the United States, and its admissions practices have long been studied as a model by medical educators. A federal finding of civil rights violations at such an institution signals that the Trump administration’s anti-DEI enforcement campaign is not limited to undergraduate admissions or humanities programs — it extends directly to graduate professional schools that train the nation’s physicians.
The Yale action is also significant because it follows so closely on the heels of last week’s targeting of the UCLA David Geffen School of Medicine. Two medical school investigations concluded within a week of each other suggest a coordinated enforcement campaign rather than isolated inquiries. The administration appears to be systematically reviewing elite professional schools for compliance with the 2023 Supreme Court ruling, and medical education has become a central front in that effort.
For patients and the broader healthcare system, the stakes of admissions policy debates at medical schools are not abstract. Physician diversity has been shown in peer-reviewed research to improve health outcomes for underserved communities, increase access to care in rural and minority-majority areas, and reduce disparities in diagnosis and treatment. If federal enforcement actions result in substantially altered admissions criteria at major medical schools, the downstream effects on the physician workforce will take a generation to manifest — but they will be real and measurable.
The Trump administration’s framing of its campaign as a defense of equal protection for white and Asian applicants resonates with a segment of the public and with the legal framework established by the Supreme Court. The administration argues it is simply enforcing existing law. Critics counter that the investigations selectively target institutions serving diverse populations and that the statistical disparities cited do not prove intentional discrimination when other admissions factors — such as geography, socioeconomic background, and extracurricular experience — are taken into account.
Economic and Global Context
The Trump administration’s anti-DEI campaign in higher education has been executed through multiple simultaneous levers. On his first day in office, Trump signed an executive order targeting what he called “radical and wasteful” DEI programs across the federal government. The administration has terminated federal research grants for work involving health disparities or efforts to diversify the scientific workforce. It also issued an executive order targeting the main medical school accrediting body, which subsequently removed health equity requirements from accreditation standards.
In January, the DOJ joined a private lawsuit against the UCLA David Geffen School of Medicine that had been filed by Do No Harm, an advocacy organization that opposes diversity initiatives in medicine. That collaboration between the federal government and a private anti-DEI organization previewed the Yale strategy: agency investigators build a formal findings letter while simultaneously aligning with outside litigants to amplify pressure on target institutions.
A coalition of 17 Democratic state attorneys general has filed a counter-lawsuit challenging a Trump administration policy that requires higher education institutions to collect data demonstrating they are not considering race in admissions. That legal battle is moving through the federal courts and could ultimately produce rulings that constrain or expand the administration’s enforcement authority in this domain.
Internationally, the United States’ approach to diversity in medical education is being watched closely by allied nations whose own medical schools operate under different legal and philosophical frameworks. Countries with universal health systems and national physician training pipelines are navigating their own debates about equity in access to medical careers.
Implications
For Yale School of Medicine specifically, the DOJ’s findings letter opens a path to federal enforcement action, including potential loss of federal funding. Yale is a major recipient of National Institutes of Health research grants and other federal dollars — funding that the administration has used as leverage against Harvard and other institutions that have resisted administration directives. The university faces a choice between accepting the DOJ’s findings and altering its admissions practices, or contesting the findings in court and risking protracted litigation.
For medical schools broadly, the Yale and UCLA findings send a clear message that no institution is too prestigious to face federal scrutiny, and that the administration intends to use the full enforcement toolkit available under civil rights law. Medical school administrators across the country will be reviewing their own admissions data and legal exposure in the coming weeks.
For aspiring physicians, particularly students from underrepresented backgrounds who have relied on holistic admissions processes to access elite medical training, the cumulative effect of these enforcement actions introduces genuine uncertainty. The legal landscape governing medical admissions is evolving rapidly, and students applying in the next two to three admissions cycles are doing so in an environment of unresolved legal and regulatory questions.
For the Trump administration, the medical school campaign provides a visible and politically popular enforcement action that reinforces the president’s core messaging on meritocracy and equal protection. The administration can point to the Supreme Court ruling as unambiguous legal authority and position itself as the defender of a settled legal standard against recalcitrant elite institutions.
Sources
“Justice Department Accuses Yale Medical School of Illegally Using Race in Admissions”
